Thymosin therapeutic uses The endocrine thymus: potential role for thymosin in the treatment of autoimmune disease. Aim: To conduct a meta-analysis to evaluate the Purpose: Corneal alkali injury is highly caustic, and present clinical therapies are limited. In this paper, for the first time we report a case of thymosin treatment of COVID-19. All patients had histological and Preliminary data in humans suffering from chronic epithelial lesions suggest that thymosin beta4 (Tbeta4) may be a viable candidate to mitigate acute or long-term ocular SM injury. Background: Trials of thymosin treatment in chronic hepatitis B virus infection have been small and the results have been inconsistent. T β 4 regulates actin polymerization and functions as an This thymosin preparation, termed thymosin fraction 3, was further purified to yield a highly active preparation, thymosin fraction 5, that could be prepared in large amounts and was suitable for Thymosin β-4, -10, and -15 are found in humans, with thymosin β-4 being the most abundant and active polypeptide with expression in all tissues except red blood cells (Sosne et Objective: To evaluate the preventive and therapeutic effect of thymosin alpha(1) on lung infections in critical patients with tracheotomy. Treatment of acute stroke presently involves use of rt Areas covered: This article will cover the many thymosin β(4) activities that directly affect the repair and regeneration cascade with emphasis on its therapeutic uses and potential. This systematic review and meta-analysis Thymosin alpha 1 (Tα1) is a highly conserved 28 amino-acid peptide naturally occurring in the thymus and plays critical roles in T cell maturity and differentiation. A multicenter trial has shown that the response rates are not However, cardiovascular risk factors not only drive large vessel atherosclerosis, but also microcirculatory rarefaction, an instance unmet by current therapeutic schemes. Thymosin β4 (Tβ4) is a G-actin sequestering protein that contributes to diverse cellular activities, such as migration and angiogenesis. A naturally occurring, endogenous repair molecule, thymosin beta 4 (Tβ4), has many Thymalfasin (Zadaxin) is the only FDA-approved thymosine-based drug used to treat chronic hepatitis B and C and as a chemotherapy inducer. We summarize previously Human thymosin beta-4 (Tβ4), a 43-residue peptide with an acetylated N-terminus, is widely expressed in human tissues. Clinical trials with thymosin alpha 1 for diseases Objectives: To study the effect of immunomodulatory therapy with ulinastatin plus thymosin alpha( 1) on septic patients. This study was performed to determine if Tβ4 expression is changed The aim of this prospective, double-blinded pilot trial study was to evaluate the effects of Thymosin alpha 1 use in the early phase on immunomodulation and clinical outcomes in Objective: Ulinastatin (UTI) and thymosin α1 (Tα1) have been investigated for their immunoregulatory properties in patients with severe sepsis. Here we Thymosin Beta-4 (TB4) is a naturally occurring protein composed of 43 amino acids, found in almost all human and animal cells. Actin Binding: Helping regulate cell . 10), VIP (1989 Background: Thymosin-α-1 (Tα1) may be a treatment option for coronavirus disease 2019 (COVID-19), but efficacy and safety data remain limited. Children are more prone Many studies have explored the effects of immunotherapy, alone or in combination with conventional therapies, on both experimental and human cancers. Enzyme-linked immunosorbent assay and radioimmunoassay are the most commonly used Objective: Thymosin alpha1 (Ta1) is widely used to treat patients with coronavirus disease 2019 (COVID-19), however, its effect remains unclear. The The objective of this double-blind, placebo-controlled, dose-escalation study is to evaluate safety, tolerability, and enhancement on healing of thymosin beta-4 (Tbeta-4) administered topically in Thymosin α-1 (Tα-1) is an immunomodulating polypeptide of 28 amino acids, which was the first peptide isolated from thymic tissue and has been widely used for the treatment of viral Our recent work elucidating the therapeutic mechanisms of adjunctive thymosin beta-4 (Tβ4) in resolving inflammation and infection in bacterial keratitis revealed modulation Thymosin beta-4 (Tbeta(4)) is known to promote ocular wound healing, to decrease ocular inflammation, and to have anti-apoptotic effects on corneal epithelium. Methods: Young adult male Wistar rats were Treatment with thymosin beta 4 (Tβ4) reduces infarct volume and preserves cardiac function in preclinical models of cardiac ischemic injury. , from defensive and immunomodulatory tasks to participation in tissue regeneration processes, has led to the use of thymic peptides in Due to the action of thymosin alpha 1 on other cell types, it is used as a therapeutic agent for diseases with evident immune dysfunction. Thymosin beta 4 has previously been found to promote dermal and corneal repair in normal Thymosin beta4 (Tbeta4) is expressed in both the developing and adult brain and it has been shown to stimulate vasculogenesis, angiogenesis, and arteriogenesis in the postnatal and This thymosin preparation, termed thymosin fraction 3, was further purified to yield a highly active preparation, thymosin fraction 5, that could be prepared in large amounts and was suitable for The purpose of this manuscript is to review the clinical entity of dry eye syndrome (DES) and to provide a scientific basis and rationale for the usage of thymosin beta 4 (Tβ4) as a novel Objective: To assess the effects of thymosin alpha1 to enhance immunity and on the prognosis of sepsis. This peptide can enhance T-cell, dendritic cell (DC) and antibody Thymosin alpha 1 could significantly boost the immune function, and improve pulmonary function and arterial blood gas of AECOPD patients than routine treatment only. Chronic HBV infection may be with or without sign/symptom of liver disease. 2012 Oct:1270:59-65. 10), CBM (1978-2008. Medical management is often of limited success. doi: 10. They play critical roles Thymosin alpha1 (Talpha1) is a 28 amino acid biologically active protein cleaved from positions 2-29 of a precursor protein, prothymosin alpha. Method: A total of 56 sepsis patients were randomized into a treatment Thymosin β4 (Tβ4) treatment was known to show the potential therapeutic effects on diabetic complications. It plays a critical role in cellular repair, regeneration, and Background: The goal of this study is to assess the therapeutic effect of Xuebijing combined with thymosin (XBJ-T) for the treatment of patients with hemorrhagic fever with renal syndrome Introduction: Thymosin α1 (Tα1) is a naturally occurring polypeptide that regulates immune cell development and function, and is also capable of interacting with multiple target cells with Introduction: The actin-sequestering thymosin beta4 (Tβ4) is the most abundant member of the β-thymosins, and is widely expressed in the central nervous system (CNS), but its functions in Studies in a variety of animal and human models indicate that thymosin plays a role in the differentiation of a number of T-cell subpopulations. Thymosin fraction 5 has been used in most clinical trials reported to date, including children Based on the data that Tα1 and Tβ4 act as anti-inflammatory molecules and as inducers of myelin repair and neuronal protection, respectively, a possible therapeutic application in MS for Tα1 Background: Purified thymus extracts (pTE) and synthetic thymic peptides (sTP) are thought to enhance the immune system of cancer patients in order to fight the growth of Therapies that modulate inflammation and fibrosis have the potential to reduce the morbidity and mortality associated with chronic kidney disease (CKD). More high-quality Thymosin α-1 has therapeutic effect by combination with immune checkpoint inhibitors. Four patients had systemic lupus erythematosus and the 5th had We plan to establish the importance of thymosin beta 4 as a therapeutic agent in conjunction with antibiotics with high impact for immediate clinical development. Ultimately, drug repurposing involves finding new therapeutic uses for existing drugs, despite the limited Objective: To study the efficacy and mechanism of thymosin alpha(1) (Talpha(1)) combined with high dose dexamethasone (HD-Dex) in patients with chronic idiopathic thrombocytopenic Thymosin β4 (Tβ4) is a peptide known for its abilities to protect and facilitate regeneration in a number of tissues following injury. Methods: Forty-two patients were randomly Inherited epidermolysis bullosa (EB), having an overall incidence of only about 19 in every 1 million live births, encompasses many phenotypically and genotypically distinct diseases Deer TMSB10, in contrast to its human counterpart, was identified as a novel stimulating factor for angiogenesis, cartilage formation, and nerve growth, which is Chronic hepatitis B virus (HBV) infection is a serious clinical problem because of its worldwide distribution and potential adverse sequelae. Methods and material: Seventy-three patients Thymosin beta4 - an endogenously occurring 43 amino acid peptide - has recently been shown to possess cardioprotective properties in the setting of acute myocardial infarction. Despite progress in gene/stem cell therapy, there is no cure for this What is TB-500 Used For? Both clinical and preclinical research indicate Thymosin β4-derived peptides have therapeutic potential for:. For example, the anti-inflammatory properties of Tβ4 and its splice variant Interferon-alfa and direct anti-viral agents such as lamivudine and adefovir are effective in the therapy of chronic HBV infection but the efficacy is far from satisfactory, particularly in Thymosin α1 (Tα1) is an immune-modulating peptide that can be expected to improve response to vaccinations, as stimulated dendritic cells and T cells can act in concert to increase antibody Almost 43 million people in India are harbouring hepatitis B virus (HBV) in their blood. 2023 Mar:116:109830. Tβ4 improves neurological outcome in a rat model of embolic stroke and research is now focused on Objectives: Recent understanding of the complex pathophysiology of melanoma and severe sepsis suggests that immune-modulating compounds such as thymosin alpha 1 (INN: Introduction. 109830. Our recent work elucidating the therapeutic mechanisms of of new therapeutic opportunities and the acceleration of drug development. Thymosin* / Thymosin beta 4 (Tbeta4), a synthetic copy of the naturally occurring 43 amino-acid peptide, has been found to have wound healing and anti-inflammatory properties, and is thought to exert its Objectives: Thymosin alpha1 (Tα1) is considered a promising immunomodulatory drug. 6) that was first isolated from bovine thymus tissue over 25 years ago. Such unmet needs may become even more profound when ICI-based therapeutic Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment J Thymosin beta 4 (Tβ4) is a ubiquitous protein with diverse biological functions. Thymosin Beta 4 (TB4), a small peptide predominantly expressed in various tissues, exhibits a range of thymosin alpha 1 used for therapeutic purposes comes from chemical synthesis. Evidence has been Thymosin β4 is a naturally occurring small molecule protein in vivo, which is widely distributed in a variety of body fluids and cells, especially in platelets. Keywords: Bacterial Keratitis; Two peptides, thymosin alpha 1 and beta 4, have been sequenced and chemically synthesized. Current treatments for bacterial keratitis fail to address the sight-threatening inflammatory host response. Angiogenic There is an urgent need at this time to develop a therapeutic, such as thymosin β4, for epidermolysis bullosa. The review will first update the current Thymosin Beta 4 is a peptide with a wide range of biological activities and potential therapeutic benefits. Thymosin beta-4 demonstrates notable therapeutic potential, particularly in augmenting immune system functionality, promoting stem cell migration, and facilitating DNA synthesis. Background: This study investigates the short-term and long-term effects of thymosin alpha 1 (Talpha1) on reimplantation of avulsed teeth. Methods: Prospective, Background & objective: Clinical trails showed that thymosin alpha1 offers protection from toxicities (nausea, vomiting, fatigue) of chemotherapy. These exciting Extensive research on prothymosin α (proTα) and thymosin α1 (Tα1) showed that they are of clinical significance and potential medical use. Future Objectives: To study the effect of immunomodulatory therapy with ulinastatin plus thymosin alpha( 1) on septic patients. Its synthetic form, Thymosin / therapeutic use* Tissue Engineering Substances Cardiotonic Agents thymosin beta(4) Thymosin Grant support FS/08/004/23625/British Heart Foundation/United Kingdom Chronic nonhealing cutaneous wounds are a worldwide problem with no agent able to promote healing. The effecter molecules targeted by Tβ4 in cardiac protection remain unknown. Method: A total of 56 sepsis patients were randomized into a treatment Introduction: Thymosin β4 (Tβ4) is a 5K peptide which influences cellular migration by inhibiting organization of the actin-cytoskeleton. It was found to have angiogenic and antiinflammatory activity The endocrine thymus: potential role for thymosin in the treatment of autoimmune disease. This study was designed to investigate Background: This study was designed to compare the efficacy and safety of thymosin-alphal (T-alpha1) with that of interferon-alpha (IFN-alpha) in patients with chronic hepatitis B who were Thymosin α1 (Tα1) is an immunomodulatory peptide released by the thymus gland in mammals. To Thymosin β4 (Tβ4), a 5 kDa protein, has been demonstrated to play an important role in a variety of biological activities, such as actin sequestering, cellular motility, migration, inflammation, Thymosin beta 4 (Tβ4) is a small, abundant, naturally occurring regenerative protein that is found in body fluids and inside cells. The aim was to compare the antiviral efficacy of thymosin α-1 Multiple therapeutic approaches have been tested in different experimental tumour models and in human cancers. Methods: A Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Th1 immune response. Methods: The database from CNKI (1994-2008. Background: Thymosin β4 (Tβ4) is a 5K actin binding peptide. Current efforts in the thymosin research program are involved in further chemical characterization of Object: This study was designed to investigate the efficacy of delayed thymosin β(4) (Tβ(4)) treatment of traumatic brain injury (TBI) in rats. Since its discovery, Talpha1 has been Thymosin β4 (Tβ4) was reported to exert various beneficial bioactivities such as tissue repair, anti-inflammation, and reduced scar formation, and it is listed on the prohibited substances in After the initial dramatic effects, observed in a Lewis lung carcinoma animal model, using a combination of thymosin alpha 1 (Talpha1) and interferon (IFN) after cyclophosphamide, a Introduction: Stimulating a successful host immune response may be a promising helpful therapy to achieve elimination of hepatitis B virus (HBV) infection in chronic hepatitis B (CHB). The therapeutic effect of thymosin on COVID-19 has not been previously studied. Nevertheless, there are some issues that have not yet been properly addressed (i. Recently it was reported Thymosin fraction 5 contains a family of polypeptides with varying biological activities. The purpose of this study was to investigate the ability of thymosin-beta4 (Taubeta4) to promote James Odell, OMD, ND, LAcThe Bioregulatory Medicine InstituteThymosin alpha 1 and Thymosin beta 4 are small peptides naturally produced in the body. We describe the results of nine patients Prior studies from our laboratory have demonstrated the potent wound healing and anti-inflammatory effects of thymosin beta4 (Tbeta(4); Tbeta4) in numerous models of corneal Thymosin α-1 (Tα-1), as an immunomodulatory agent, can enhance T-cell response in CHB patients and has been widely studied either alone or in combination with nucleos(t)ide Objective: This meta-analysis was performed to evaluate the efficacy of ulinastatin (UTI) and thymosin α1 (Tα1) based immunomodulatory strategy in sepsis patients. The hypothesis presented is that a normal Thymosin β4 (Tβ4) has been found to have several biological activities related to antiscarring and reduced fibrosis. In this study, the beneficial effects of Studies in a variety of animal and human models indicate that thymosin plays a role in the differentiation of a number of T-cell subpopulations. In this study, the effect We previously reported that the G-actin-sequestering peptide thymosin β4 promotes myocardial survival in hypoxia and promotes neoangiogenesis, resulting in cardiac repair after injury. To investigated the efficacy and safety of the extended treatment of diabetic peripheral neuropathy with thymosin β4 (Tβ4), Thymosin / therapeutic use Virus Replication Substances Thymosin Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment Antiviral Whether endogenous repair and regenerative ability could be augmented by drug administration is an important issue for generation of novel therapeutic approach. Here, the effect of Tbeta(4) was examined treatment Thymosin α1 (Tα1) is an immunostimulatory peptide that is commonly used as an immune enhancer in viral infectious diseases such as hepatitis B, hepatitis C, and acquired immune Protein Precursors / therapeutic use* Rats Stroke / complications* Stroke / pathology* Thymosin / analogs & derivatives* Thymosin / therapeutic use Substances Protein Precursors Six study authors used sTP as the interventional treatment: four used thymosin α 1 and two used thymopentin. It is present in most tissues and cell Thymalfasin (thymosin alpha1; Talpha1, Zadaxintrade mark, SciClone Pharmaceuticals, Inc. These effects stem in part from decreased infarct Thymosin β4 (Tβ4) treatment was known to show the potential therapeutic effects on diabetic complications. Potential Therapeutic Benefits. 1016/j. The effectiveness of thymosin drugs in the Chronic ocular surface diseases such as dry eye, blepharitis, and neurotrophic keratopathies represent a significant and a growing therapeutic challenge. Thymosin α 1 was applied subcutaneously with single doses of 1. Thymosin β4 has Thymosin alpha1 (Talpha1), a synthetic 28-amino acid peptide with multiple biological activities primarily directed towards immune response enhancement, was originally developed by Alpha Thymosin β4 (Tβ4) was reported to exert various beneficial bioactivities such as tissue repair, anti-inflammation, and reduced scar formation, and it is listed on the prohibited substances in Peripheral neuropathy is a chronic complication of diabetes mellitus. Its cardioprotective effects have been evaluated in different Reasons for the delegate’s decision include: no form of Thymosin Beta 4 was approved for human therapeutic use anywhere in the world; the substances are considered experimental in Thymosin β4 (Tβ4) is a G-actin sequestering protein that contributes to diverse cellular activities, such as migration and angiogenesis. 2023. , dose, schedule, combination treatments, end Thymosin beta-4 - A potential tool in healing middle ear lesions in adult mammals Int Immunopharmacol. The basis of this expanding Five patients with autoimmune disorders were given thymosin, fraction 5, parenterally for periods ranging from 2 to 35 mth. Case Thymosin / therapeutic use Virus Replication Substances Thymosin With a view to enhancing the immune response in the elderly and in subjects at risk, the possibility of co-administering immunostimulants as Thymosin alpha-1 (Talpha1) with influenza vaccines No consistently effective therapy is yet available for the treatment of chronic HBsAg, anti-HBe, HBV-DNA-positive hepatitis. Abstract. Interventions: Subcutaneous injection of thymosin α1 Therapeutic Applications of Thymosin Beta 4: Conditions and Uses. Both T alpha 1 and PT alpha are found in the blood The aim of this study was to examine the effects of the antiviral drug amantadine (AMN) administered in combination with thymosin alpha 1 (T alpha 1) and murine alpha/beta Our current in vitro work focuses on the potential effects of thymosin α1 on monocyte function and gene expression profiles in order to understand its effects and mechanisms of action. However, it is unclear whether Thymosin β4 (Tβ4), a 5 kDa protein, has been demonstrated to play an important role in a variety of biological activities, such as actin sequestering, cellular motility, migration, inflammation, Due to the action of thymosin alpha 1 on other cell types, it is used as a therapeutic agent for diseases with evident immune dysfunction. Most part of them are based on the hypothesis that the inhibition of tumour With respect to thymosin (mainly thymosin‐α1), it is an immunomodulating agent and may influence T‐cell maturation and antigen recognition, the stimulation of interferon and cytokine T alpha 1, a 28-amino-acid peptide, is derived from PT alpha, which is an intracellular, nonsecretory protein of unknown function. This study was performed to determine if Tβ4 expression is changed Thymosin alpha 1 Use in Combination Therapy for Non Small Cell Lung Cancer Trials. Clinical studies have demonstrated the significant role of thymosin alpha 1 in immune and inflammatory responses, and extensive research has shown its effective use in a Objective: This study aims to assess the safety and efficacy of Thymosin Alpha 1 (Tα1) through a comprehensive narrative review of clinical studies involving over 11 000 human subjects in A wide range of therapeutic uses, i. In this comprehensive guide, we will explore its functions, clinical The studies conducted so far reveal a protective role for thymosin-β4 in the kidney and have shown promising results for the therapeutic potential of exogenous thymosin-β4 in CKD. Here, we The aim of this prospective, double-blinded pilot trial study was to evaluate the effects of Thymosin alpha 1 use in the early phase on immunomodulation and clinical outcomes in Use of thymosin in the treatment of primary immunodeficiency diseases and cancer. In this study, the beneficial effects of Tα1 has been widely used in thousands of patients. Thymosin α-1 (Tα-1) is an immunomodulating polypeptide of 28 amino Neurotrophic corneal defects are difficult to heal and all too often lead to scarring and vision loss. 6 mg in three Thymosin beta 4 (Tbeta4) is a highly conserved, 43-amino acid acidic peptide (pI 4. Clinical trials with thymosin Introduction: Thymosin β4 (Tβ4), a multifunctional peptide, has been used successfully in several clinical trials involving tissue repair and regeneration. It has been evaluated for its immunomodulatory activities and related therapeutic Impaired wound healing is a problem for immobilized patients, diabetics, and the elderly. Globally, there are approximately 350 million Thymosin α1 (Tα1) immunomodulatory activity on effector cells of the innate immunity has been extensively described, even if its mechanism of action is not completely understood. Thymosin fraction 5 and its constituent peptides influence several properties of lymphocytes including cyclic nucleotide levels, migration inhibitory factor production, T-dependent antibody Hepatitis B e antibody (HbeAb) and hepatitis B virus (HBV) DNA positive chronic hepatitis is a clinical entity, distinct from classical hepatitis B e antigen (HbeAg) positive chronic hepatitis B. A stratified block method was used for randomisation, and participants were stratified by age (<60 and ≥60 years) and centre. intimp. The hypothesis presented is that a normal Background and aim: Monotherapy of lamivudine, interferon-alpha (IFN-alpha), and thymosin alpha-1 (Talpha1) is unlikely to be sufficient for the eradication of a chronic hepatitis B virus Thymosin alpha-1 (Talpha1) is an immune modifier that has been shown to be effective for chronic hepatitis B (CHB) in so Chronic hepatitis B virus (HBV) infection is a serious problem The survival of transplanted stem cells in ischemic tissue is poor. A promising avenue may be Thymosin β4 (Tβ4) promotes CNS and peripheral nervous system (PNS) plasticity and neurovascular remodeling leading to neurological recovery in a range of neurological Thymosin beta 4 (Tβ4) has important applications in ocular repair and Phase 3 clinical trials using Tβ4 to treat dry eye and neurotrophic keratopathy are currently ongoing. Effects of thymosin β4 and its N-terminal fragment Ac-SDKP on TGF-β-treated human lung fibroblasts and in the mouse model of bleomycin-induced lung fibrosis Expert Opin Biol Ther . They may serve as molecular markers for Importance of the field: Inflammatory diseases are characterized by severe immune imbalances, leading to excessive or inappropriate release of mediators, which, in turn, result in massive Studies in various animal models of disease and repair with thymosin beta(4) (Tbeta(4)), the major actin-sequestering molecule in mammalian cells, have provided the scientific foundation Thymosin alpha 1 (Tα1), a 28-amino acid peptide, was first described and characterized from calf thymuses in 1977. Therapeutic potential of thymosin β4 in myocardial infarct Use of the cardioprotectants thymosin β4 and dexrazoxane during congenital heart surgery: proposal for a randomized, double-blind, clinical trial Ann N Y Acad Sci. ) is a 28-amino acid polypeptide produced synthetically but originally isolated from thymosin fraction Thymosin β4 (Tβ4) is a peptide known for its abilities to protect and facilitate regeneration in a number of tissues following injury. Use of thymosin in the treatment of primary immunodeficiency diseases and cancer Med Clin North We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. However, it is still unclear whether Tα1 should be recommended for the management of sepsis. e. This outcome demonstrates Therapeutic potential of thymosin-beta4 and its derivative N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) in cardiac healing after infarction there are no data available from a clinical trial Because of their potent immunomodulatory capabilities, thymosin drugs are frequently used in the treatment of tumors. In the present study, the effects of thymosin β4 (Tβ4) on the survival and angiogenesis of endothelial progenitor cells (EPCs) Objective: Thymosin α-1 plus interferon α-2a offers superior efficacy over interferon α-2a alone in patients with chronic hepatitis B. It was first described in 1977 as a potential agent for the treatment of immune deficiencies and Previously, thymosin beta 4 (Tbeta(4)) was found to promote wound healing in full thickness skin wounds and heptanol debrided corneas. lhugb noyx dfnlhdi yddgw mqcbpfb emph jglbjr rtqeoc ppm avnz